What is Citius Oncology, Inc.'s deferred contract costs?

Citius Oncology, Inc. (CTOR) reported deferred contract costs of $169.25K in Q1 2026.

Citius Oncology, Inc. CTOR Deferred contract costs

Deferred contract costs at other companies

Nano Nuclear EnergyNNE

$385.5K—

CYP

Cypherpunk Technologies Inc. Common StockCYPH

$385K—

FRP HoldingsFRPH

$3.64M+58.5%

KEE

Keel Infrastructure Corp. Common StockKEEL

$1.67M—

High Roller TechnologiesROLR

$0—

MatsonsMATX

$99.1M+27.4%

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-75.9%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredCosts.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s deferred contract costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s deferred contract costs?: Citius Oncology, Inc. (CTOR) reported deferred contract costs of $169.25K in Q1 2026.